Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant...
Patent
1988-07-07
1990-06-05
Maples, John S.
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
424 9, A61K 4902
Patent
active
049312707
ABSTRACT:
Abnormalitites in the distribution of a dopamine D.sub.2 receptors in humans and other mammals are detected by
REFERENCES:
Ames, et al, "The Synthesis of Alkoxy-1,2,3,4-tetrahydronaphthalene Derivates. Part I. 2-Amino, Alkylamino-, and Dialkylamino-derivatives," J. Chem. Soc., 2636 (1986).
Andreasen, et al., "Brain Imaging: Application in Psychiatry", Science 239, 1381-1388 (1988).
Arnett, et al., "Improved Delineation of Human Dopamine Receptors Using [.sup.18 F]-N-Methylspiroperidol and PET", J. Nucl. Med. 27(12) 1878-1882 (1986).
Berridge, "Chemistry of Fluorine-18 Radiopharmaceuticals", Appl. Radiat. Isot. 37(8) 685-693 (1986).
Chi et al, "A Rapid and Efficient Method for Fluoroalkylation of Amines and Amides. Development of a Method Suitable for Incorporation or the Short-Lived Positron Emitting Radionuclide Fluorine-18", J. Org. Chem. 52 658-664 (1987).
Chi, et al, "Synthesis of No-Carrier-Added N-([.sup.18 F]Fluoroalkyl)Spiperone Derivatives", Appl. Radiat. Isot. 37(12) 1173-1180 (1986).
Crowe, et al., "Studies in the Thiophene Series, VI. Azlactones and Rhodanines Prepared from 2-Thenaldehyde and Some Substituted 2-Thenaldehydes", J. Org. Chem 15, 81 (1950).
Daly, et al, "Structure-Activity Relationship for N.sup.6 -Substituted Adenosines at a Brain A.sub.1 -Adenosine Receptor with a Comparison to an A.sub.2 -Adenosine Receptor Regulating Coronary Blood Flow", Biochem. Pharmac. 35(15) 2467-2481 (1986).
Farde, et al, "Quantitative Analysis of D.sub.2 Dopamine Receptor Binding in the Living Human Brain by PET", Science 231, 258-261 (1986).
Hagglund, et al, "Dopamine Receptor Properties in Parkinson's Disease and Huntington's Chorea Evaluated by Positron Emission Tompography Using .sup.11 C-N-Methyl-Spiperone", Acta Neurol Scand 75:87-94 (1987).
Hoffmann, "Aliphatic Fluorides, II. 1-Halogen Fluoroalkanes", J. Org. Chem. 15, 425 (1950).
Mulder, et al, "Kinetic and Pharmacological Profiles of the In Vitro Binding of the Potent Dopamine Agonist [.sup.3 H]N,N-Dipropyl-5, 6-Dihydroxy-2-Aminotetralin to Rat Straital Membranes", Eur. J. Pharmac. 112 73-79 (1985).
Phelps, et al, "Positron Emission Tomography: Human Brain Function and Biochemistry", Science 228 (4701) 799-809 (1985).
Raichle, "Positron Emission Tomography", Ann. Rev. Neurosci. 6:249-267 (1983).
Seeman, "Brain Dopamine Receptors", Pharmacol. Rev. 32(3) 229-313 (1980).
Seeman, et al, "Dopamine D.sub.2 Receptor Binding Sites for Agonists, A Tetrahedral Model", Molec. Pharmacol. 28:391-399 (1985).
Van Der Werf, et al, "Synthesis and In Vivo Distribution in Rat Brain of .sup.11 C-Labelled N-Alkylated ADTN Derivatives", Int. J. Appl. Radit. Isot. 35(5) 377-381 (1984).
Wong, et al, "Positron Emission Tomography Reveals Elevated D.sub.2 Dopamine Receptors in Drug-Naive Schizophrenics", Science 234, 1558-1663 (1986).
Horn Alan S.
Jerabek Paul A.
Peck James V.
Baran Robert J.
Bostich June M.
Maples John S.
Nelson Research & Development
LandOfFree
Method for detecting dopaminergic diseases using fluorine-18 rad does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for detecting dopaminergic diseases using fluorine-18 rad, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for detecting dopaminergic diseases using fluorine-18 rad will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-490633